• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Gen­fit's up to €185M roy­al­ty deal; J&J’s Trem­fya gets a Crohn's ap­proval

2 months ago
News Briefing

As­traZeneca puts $2.5B to­ward first vac­cine fac­to­ry and sec­ond R&D site in Chi­na

2 months ago
R&D
China

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

2 months ago
Deals
China

John­son & John­son ear­marks $55B to boost US ca­pac­i­ty 

2 months ago
Pharma
Manufacturing

Bridge­Bio, Ed­i­tas fi­nance chiefs de­part; For­mer FDA No. 2 joins Re­cur­sion's board

2 months ago
Peer Review

Ex­clu­sive: Roivant-backed Van­tAI de­buts AI mod­el Neo-1, tak­ing ‘the big next step’ af­ter Al­phaFold 3

2 months ago
AI

Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

2 months ago
Pharma
FDA+

CDC vac­cine meet­ing, de­layed ear­li­er this year, is resched­uled

2 months ago
R&D
Pharma

Akero ex­ec calls FDA's ac­cel­er­at­ed ap­proval guid­ance for MASH drugs 'bizarre'

2 months ago
R&D
Pharma

Two-thirds of re­cent rare dis­ease drugs re­lied on just one tri­al, plus con­fir­ma­to­ry ev­i­dence, FDA team finds

2 months ago
FDA+

No­vo Nordisk says new ear­ly R&D struc­ture will ‘fu­ture-proof’ its busi­ness

2 months ago
Pharma

Cal­ley Means joins White House as a spe­cial gov­ern­ment em­ploy­ee, will as­sist with MA­HA poli­cies

2 months ago
People

SV Health In­vestors nabs $250M to fund de­men­tia-fo­cused biotechs

2 months ago
Financing
Startups

Google is build­ing AI health­care helpers

2 months ago
Health Tech

As­cendis’ Chi­na joint ven­ture, Visen Phar­ma­ceu­ti­cals, prices $86M Hong Kong IPO

2 months ago
Financing
Startups

Mer­ck to lay off 163 work­ers in Penn­syl­va­nia; Del­pharm gets $60M from Cana­di­an gov­ern­ment 

2 months ago
Manufacturing

El­e­va­tion On­col­o­gy stops work on ADC, lays off work­ers; As­traZeneca’s CEPI fund­ing

2 months ago
News Briefing

Like its ri­vals, Op­tum Rx is chang­ing its pay­ment mod­els

2 months ago
Health Tech

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

2 months ago
In Focus
Diagnostics

Up­dat­ed: Monte Rosa re­ports first da­ta for mol­e­c­u­lar glue pro­gram li­censed to No­var­tis

2 months ago
R&D

Paratek boosts com­mer­cial port­fo­lio in move to buy Opti­nose and its nasal spray

2 months ago
Deals
Pharma

Sanofi to pay $600M up­front for Dren Bio’s bis­pe­cif­ic B cell de­pleter

2 months ago
Deals

A Cal­i­for­nia health tech com­pa­ny is let­ting AI run med­ical vis­its, from in­take to di­ag­no­sis

2 months ago
AI
In Focus

No­var­tis touts Zol­gens­ma da­ta in old­er kids as it read­ies reg­u­la­to­ry fil­ings

2 months ago
Pharma
First page Previous page 26272829303132 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News